相关实验视频
Updated: Jan 18, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
913
患有恶性瘤的肥胖患者:病例系列和文献综述
Ping Liang1, Meng-Yuan Zhu2, Ruixia Yang1
1Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Changan District, No. 12, Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Discover oncology
|June 6, 2025
概括
肥胖的癌症患者通常因毒性问题而接受较低的化疗剂量. 这项研究建议使用实际体重来计算用于确定化疗剂量的身体表面积,而不是估计的体重.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 肥胖症在癌症治疗中存在独特的挑战,原因是药物药理动力学的改变.
- 缺乏针对肥胖患者抗癌药物剂量的具体指导方针,是因为他们在临床试验中代表性不足.
- 肥胖与某些癌症有关,使管理复杂化.
研究的目的:
- 报告三名患有恶性瘤的肥胖患者的抗瘤治疗.
- 审查有关肥胖患者抗癌药物剂量的文献.
- 为优化肥胖癌症患者的化疗提供数据.
主要方法:
- 三名患有恶性瘤的肥胖患者的案例研究.
- 在肥胖人口中对抗癌药物剂量调整的文献综述.
- 基于患者体重和药物特性,分析卡博普拉丁和甲铁酸剂量策略.
主要成果:
- 由于神经毒性风险和脏分泌的原因,卡博普拉丁被使用固定剂量.
- 甲托雷克萨特的剂量是基于实际体重,保持治疗药物度,没有严重的不良事件.
- 化学疗法毒性评估传统上依赖于实际体重,但肥胖患者往往接受降低剂量.
结论:
- 支持化疗使用与肥胖患者中毒性增加之间的直接联系的证据有限.
- 肥胖癌症患者的化疗剂量应根据实际体重计算的身体表面积 (BSA) 来确定.
- 避免在肥胖患者中使用估计或理想的体重来计算化疗剂量.
相关概念视频
Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Drug Dosing: Obese Patients
226
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
226
